Plasma metabolome analysis of patients with major depressive disorder

Noriyuki Kawamura, Kosaku Shinoda, Hajime Sato, Kazunori Sasaki, Makoto Suzuki, Kumi Yamaki, Tamaki Fujimori, Hiroyuki Yamamoto, Douglas Osei-Hyiaman, Yoshiaki Ohashi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aim: This study sought to characterize the plasma metabolite profiling of patients with major depressive disorder (MDD). Methods: Psychiatric assessments were made with the Structured Clinical Interview for DSM-IV Axis I Disorders. In the exploratory cohort, plasma metabolite profiles of 34 MDD patients and 31 mentally healthy controls were compared using capillary electrophoresis-mass spectrometry. Among the candidate metabolites, we focused on a metabolite showing the largest difference. The absolute concentrations were measured in two cohorts from a psychiatric primary care clinic to characterize the accuracy of the metabolite biomarker. Results: Among 23 metabolites significantly lower in the MDD group than in healthy controls, we focused on phosphoethanolamine (PEA) as a candidate. The reduction of PEA levels in MDD was checked in independent clinical sample sets. An ion-chromatography-fluorescence detection method was developed to measure plasma PEA levels. In the preliminary cohort, we examined 34 MDD and 43 non-MDD subjects. The area under the receiver–operator curve (AUC) was 0.92, with sensitivity/specificity greater than 88%, at a cut-off of 1.46 μM. In the checking cohort, with 10 MDD and 13 non-MDD subjects, AUC was 0.89, with sensitivity/specificity of 86% and 100%, respectively, at a cut-off of 1.48 μM. Plasma PEA inversely correlated with MDD severity, depressed mood, loss of interest, and psychomotor retardation. Conclusion: These results suggest that plasma PEA level could be a candidate biomarker of MDD in the clinical setting. Further studies comparing MDD and mentally healthy controls are needed to confirm the utility of PEA as a biomarker for depression.

Original languageEnglish (US)
Pages (from-to)349-361
Number of pages13
JournalPsychiatry and Clinical Neurosciences
Volume72
Issue number5
DOIs
StatePublished - May 1 2018
Externally publishedYes

Fingerprint

Metabolome
Major Depressive Disorder
Biomarkers
Depressive Disorder
Area Under Curve
Psychiatry
Sensitivity and Specificity
Capillary Electrophoresis
Diagnostic and Statistical Manual of Mental Disorders
phosphorylethanolamine
Chromatography
Mass Spectrometry
Primary Health Care
Fluorescence
Interviews
Ions
Depression

Keywords

  • biomarker
  • diagnosis
  • major depressive disorder
  • metabolomics
  • phosphoethanolamine

ASJC Scopus subject areas

  • Neuroscience(all)
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Kawamura, N., Shinoda, K., Sato, H., Sasaki, K., Suzuki, M., Yamaki, K., ... Ohashi, Y. (2018). Plasma metabolome analysis of patients with major depressive disorder. Psychiatry and Clinical Neurosciences, 72(5), 349-361. https://doi.org/10.1111/pcn.12638

Plasma metabolome analysis of patients with major depressive disorder. / Kawamura, Noriyuki; Shinoda, Kosaku; Sato, Hajime; Sasaki, Kazunori; Suzuki, Makoto; Yamaki, Kumi; Fujimori, Tamaki; Yamamoto, Hiroyuki; Osei-Hyiaman, Douglas; Ohashi, Yoshiaki.

In: Psychiatry and Clinical Neurosciences, Vol. 72, No. 5, 01.05.2018, p. 349-361.

Research output: Contribution to journalArticle

Kawamura, N, Shinoda, K, Sato, H, Sasaki, K, Suzuki, M, Yamaki, K, Fujimori, T, Yamamoto, H, Osei-Hyiaman, D & Ohashi, Y 2018, 'Plasma metabolome analysis of patients with major depressive disorder', Psychiatry and Clinical Neurosciences, vol. 72, no. 5, pp. 349-361. https://doi.org/10.1111/pcn.12638
Kawamura, Noriyuki ; Shinoda, Kosaku ; Sato, Hajime ; Sasaki, Kazunori ; Suzuki, Makoto ; Yamaki, Kumi ; Fujimori, Tamaki ; Yamamoto, Hiroyuki ; Osei-Hyiaman, Douglas ; Ohashi, Yoshiaki. / Plasma metabolome analysis of patients with major depressive disorder. In: Psychiatry and Clinical Neurosciences. 2018 ; Vol. 72, No. 5. pp. 349-361.
@article{c412c9a3010b44529abe3fff9c3dfcb1,
title = "Plasma metabolome analysis of patients with major depressive disorder",
abstract = "Aim: This study sought to characterize the plasma metabolite profiling of patients with major depressive disorder (MDD). Methods: Psychiatric assessments were made with the Structured Clinical Interview for DSM-IV Axis I Disorders. In the exploratory cohort, plasma metabolite profiles of 34 MDD patients and 31 mentally healthy controls were compared using capillary electrophoresis-mass spectrometry. Among the candidate metabolites, we focused on a metabolite showing the largest difference. The absolute concentrations were measured in two cohorts from a psychiatric primary care clinic to characterize the accuracy of the metabolite biomarker. Results: Among 23 metabolites significantly lower in the MDD group than in healthy controls, we focused on phosphoethanolamine (PEA) as a candidate. The reduction of PEA levels in MDD was checked in independent clinical sample sets. An ion-chromatography-fluorescence detection method was developed to measure plasma PEA levels. In the preliminary cohort, we examined 34 MDD and 43 non-MDD subjects. The area under the receiver–operator curve (AUC) was 0.92, with sensitivity/specificity greater than 88{\%}, at a cut-off of 1.46 μM. In the checking cohort, with 10 MDD and 13 non-MDD subjects, AUC was 0.89, with sensitivity/specificity of 86{\%} and 100{\%}, respectively, at a cut-off of 1.48 μM. Plasma PEA inversely correlated with MDD severity, depressed mood, loss of interest, and psychomotor retardation. Conclusion: These results suggest that plasma PEA level could be a candidate biomarker of MDD in the clinical setting. Further studies comparing MDD and mentally healthy controls are needed to confirm the utility of PEA as a biomarker for depression.",
keywords = "biomarker, diagnosis, major depressive disorder, metabolomics, phosphoethanolamine",
author = "Noriyuki Kawamura and Kosaku Shinoda and Hajime Sato and Kazunori Sasaki and Makoto Suzuki and Kumi Yamaki and Tamaki Fujimori and Hiroyuki Yamamoto and Douglas Osei-Hyiaman and Yoshiaki Ohashi",
year = "2018",
month = "5",
day = "1",
doi = "10.1111/pcn.12638",
language = "English (US)",
volume = "72",
pages = "349--361",
journal = "Psychiatry and Clinical Neurosciences",
issn = "1323-1316",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Plasma metabolome analysis of patients with major depressive disorder

AU - Kawamura, Noriyuki

AU - Shinoda, Kosaku

AU - Sato, Hajime

AU - Sasaki, Kazunori

AU - Suzuki, Makoto

AU - Yamaki, Kumi

AU - Fujimori, Tamaki

AU - Yamamoto, Hiroyuki

AU - Osei-Hyiaman, Douglas

AU - Ohashi, Yoshiaki

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Aim: This study sought to characterize the plasma metabolite profiling of patients with major depressive disorder (MDD). Methods: Psychiatric assessments were made with the Structured Clinical Interview for DSM-IV Axis I Disorders. In the exploratory cohort, plasma metabolite profiles of 34 MDD patients and 31 mentally healthy controls were compared using capillary electrophoresis-mass spectrometry. Among the candidate metabolites, we focused on a metabolite showing the largest difference. The absolute concentrations were measured in two cohorts from a psychiatric primary care clinic to characterize the accuracy of the metabolite biomarker. Results: Among 23 metabolites significantly lower in the MDD group than in healthy controls, we focused on phosphoethanolamine (PEA) as a candidate. The reduction of PEA levels in MDD was checked in independent clinical sample sets. An ion-chromatography-fluorescence detection method was developed to measure plasma PEA levels. In the preliminary cohort, we examined 34 MDD and 43 non-MDD subjects. The area under the receiver–operator curve (AUC) was 0.92, with sensitivity/specificity greater than 88%, at a cut-off of 1.46 μM. In the checking cohort, with 10 MDD and 13 non-MDD subjects, AUC was 0.89, with sensitivity/specificity of 86% and 100%, respectively, at a cut-off of 1.48 μM. Plasma PEA inversely correlated with MDD severity, depressed mood, loss of interest, and psychomotor retardation. Conclusion: These results suggest that plasma PEA level could be a candidate biomarker of MDD in the clinical setting. Further studies comparing MDD and mentally healthy controls are needed to confirm the utility of PEA as a biomarker for depression.

AB - Aim: This study sought to characterize the plasma metabolite profiling of patients with major depressive disorder (MDD). Methods: Psychiatric assessments were made with the Structured Clinical Interview for DSM-IV Axis I Disorders. In the exploratory cohort, plasma metabolite profiles of 34 MDD patients and 31 mentally healthy controls were compared using capillary electrophoresis-mass spectrometry. Among the candidate metabolites, we focused on a metabolite showing the largest difference. The absolute concentrations were measured in two cohorts from a psychiatric primary care clinic to characterize the accuracy of the metabolite biomarker. Results: Among 23 metabolites significantly lower in the MDD group than in healthy controls, we focused on phosphoethanolamine (PEA) as a candidate. The reduction of PEA levels in MDD was checked in independent clinical sample sets. An ion-chromatography-fluorescence detection method was developed to measure plasma PEA levels. In the preliminary cohort, we examined 34 MDD and 43 non-MDD subjects. The area under the receiver–operator curve (AUC) was 0.92, with sensitivity/specificity greater than 88%, at a cut-off of 1.46 μM. In the checking cohort, with 10 MDD and 13 non-MDD subjects, AUC was 0.89, with sensitivity/specificity of 86% and 100%, respectively, at a cut-off of 1.48 μM. Plasma PEA inversely correlated with MDD severity, depressed mood, loss of interest, and psychomotor retardation. Conclusion: These results suggest that plasma PEA level could be a candidate biomarker of MDD in the clinical setting. Further studies comparing MDD and mentally healthy controls are needed to confirm the utility of PEA as a biomarker for depression.

KW - biomarker

KW - diagnosis

KW - major depressive disorder

KW - metabolomics

KW - phosphoethanolamine

UR - http://www.scopus.com/inward/record.url?scp=85043267038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043267038&partnerID=8YFLogxK

U2 - 10.1111/pcn.12638

DO - 10.1111/pcn.12638

M3 - Article

C2 - 29356314

AN - SCOPUS:85043267038

VL - 72

SP - 349

EP - 361

JO - Psychiatry and Clinical Neurosciences

JF - Psychiatry and Clinical Neurosciences

SN - 1323-1316

IS - 5

ER -